{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:50:55Z","timestamp":1761540655959},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2005,8,1]],"date-time":"2005-08-01T00:00:00Z","timestamp":1122854400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"published-print":{"date-parts":[[2005,8]]},"DOI":"10.1007\/s11239-005-2465-4","type":"journal-article","created":{"date-parts":[[2005,8,30]],"date-time":"2005-08-30T13:38:24Z","timestamp":1125409104000},"page":"23-26","source":"Crossref","is-referenced-by-count":1,"title":["Inhibition of Desmoteplase-Induced Fibrinolytic Activity In Vitro"],"prefix":"10.1007","volume":"20","author":[{"given":"Johannes J. M. L.","family":"Hoffmann","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Oliver","family":"Kops","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"2465_CR1","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1055\/s-0038-1661632","volume":"56","author":"MA Mohler","year":"1986","unstructured":"Mohler MA, Refino CJ, Chen SA, Chen AB, Hotchkiss AJ. D-Phe-Pro-Arg-chloromethylketone: Its potential use in inhibiting the formation of in vitro artifacts in blood collected during tissue-type plasminogen activator thrombolytic therapy. Thromb Haemost 1986;56:160\u2013164.","journal-title":"Thromb Haemost"},{"key":"2465_CR2","first-page":"506","volume":"235","author":"M Verstraete","year":"1985","unstructured":"Verstraete M, Bounameaux H, de Cock F, Van de Werf F, Collen D. Pharmacokinetics and systemic fibrinogenolytic effects of recombinant human tissue-type plasminogen activator (rt-PA) in humans. J Pharmacol Exp Ther 1985;235:506\u2013512.","journal-title":"J Pharmacol Exp Ther"},{"key":"2465_CR3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/0049-3848(88)90180-6","volume":"50","author":"HD Garabedian","year":"1988","unstructured":"{Garabedian HD, Gold HK, Leinbach RC, Yasuda T, Johns JA, Thornton D, Collen D. Laboratory monitoring of hemostasis during thrombolytic therapy with recombinant human tissue-type plasminogen activator. Thromb Res 1988;50:121\u2013133.","journal-title":"Thromb Res"},{"key":"2465_CR4","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1055\/s-0038-1646016","volume":"58","author":"E Seifried","year":"1987","unstructured":"Seifried E, Tanswell P. Comparison of specific antibody, D-Phe-Pro-Arg-CH2Cl and aprotinin for prevention of in vitro effects of recombinant tissue-type plasminogen activator on haemostasis parameters. Thromb Haemost 1987;58:921\u2013926.","journal-title":"Thromb Haemost"},{"key":"2465_CR5","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1097\/00001721-199104000-00010","volume":"2","author":"JJ Hoffmann","year":"1991","unstructured":"Hoffmann JJ, Vijgen M. Prevention of in vitro fibrinogenolysis during laboratory monitoring of thrombolytic therapy with streptokinase or APSAC. Blood Coagul Fibrinolysis 1991;2:279\u2013284.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2465_CR6","unstructured":"Grunewald M, Seifried E. Laboratory monitoring of thrombolytic therapy in clinical practice and research. Z Kardiol 1993;(82 Suppl 2):129\u2013135."},{"key":"2465_CR7","doi-asserted-by":"crossref","first-page":"17947","DOI":"10.1016\/S0021-9258(19)84664-1","volume":"264","author":"SJ Gardell","year":"1989","unstructured":"Gardell SJ, Duong LT, Diehl RE, York JD, Hare TR, Register RB, Jacobs JW, Dixon RA, Friedman PA. Isolation, characterization, and cDNA cloning of a vampire bat salivary plasminogen activator. J Biol Chem 1989;264:17947\u201317952.","journal-title":"J Biol Chem"},{"key":"2465_CR8","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1182\/blood.V79.5.1213.1213","volume":"79","author":"W Witt","year":"1992","unstructured":"Witt W, Baldus B, Bringmann P, Cashion L, Donner P, Schleuning WD. Thrombolytic properties of Desmodus rotundus (vampire bat) salivary plasminogen activator in experimental pulmonary embolism in rats. Blood 1992;79:1213\u20131217.","journal-title":"Blood"},{"key":"2465_CR9","first-page":"118","volume":"31","author":"WD Schleuning","year":"2001","unstructured":"Schleuning WD. Vampire bat plasminogen activator DSPA-alpha-1 (desmoteplase): A thrombolytic drug optimized by natural selection. Haemostasis 2001;31:118\u2013122.","journal-title":"Haemostasis"},{"key":"2465_CR10","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/01.STR.0000049764.49162.76","volume":"34","author":"GT Liberatore","year":"2003","unstructured":"Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): A unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke 2003;34:537\u2013543.","journal-title":"Stroke"},{"key":"2465_CR11","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1055\/s-0038-1651055","volume":"57","author":"PW Koppert","year":"1987","unstructured":"Koppert PW, Kuipers W, Hoegee-de Nobel B, Brommer EJ, Koopman J, Nieuwenhuizen W. A quantitative enzyme immunoassay for primary fibrinogenolysis products in plasma. Thromb Haemost 1987;57:25\u201328.","journal-title":"Thromb Haemost"},{"key":"2465_CR12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1097\/00001721-199304010-00006","volume":"4","author":"JL Francis","year":"1993","unstructured":"Francis JL, Howard C. The effect of aprotinin on the response of the activated partial thromboplastin time (APTT) to heparin. Blood Coagul Fibrinolysis 1993;4:35\u201340.","journal-title":"Blood Coagul Fibrinolysis"},{"key":"2465_CR13","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/0033-0620(92)90022-R","volume":"34","author":"EG Bovill","year":"1992","unstructured":"Bovill EG, Becker R, Tracy RP. Monitoring thrombolytic therapy. Prog Cardiovasc Dis 1992;34:279\u2013294.","journal-title":"Prog Cardiovasc Dis"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-005-2465-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11239-005-2465-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-005-2465-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,16]],"date-time":"2021-07-16T21:27:50Z","timestamp":1626470870000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11239-005-2465-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005,8]]}},"alternative-id":["2465"],"URL":"https:\/\/doi.org\/10.1007\/s11239-005-2465-4","relation":{},"ISSN":["0929-5305","1573-742X"],"issn-type":[{"value":"0929-5305","type":"print"},{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8]]}}}